. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Acad Radiol. 2020 Nov 5;29(Suppl 1):S145–S154. doi: 10.1016/j.acra.2020.10.020

Table 2.

Radiomics features demonstrating a significant difference between molecular subtypes of breast cancer on pretreatment MRI in patients undergoing neoadjuvant chemotherapy

Radiomics feature	HER2+ (n=73) Median (range)	Luminal (n=112) Median (range)	TNBC (n=74) Median (range)	P value
Volume (mm³)	4297.46 (368.84, 84519.84)	7684.77 (290.55, 103474.46)	7483.03 (783.75, 100355.29)	0.008
Longest axial diameter (mm)	27.1 (9.24, 99.54)	34.89 (8.79, 110.54)	33.49 (14.04, 100.25)	0.009
Longest volumetric diameter (mm)	30.5 (16.32, 93.63)	36.48 (14.16, 106.07)	33.02 (16.69, 93.29)	0.01
Minimum signal int ensity (SSF=4 mm)	−0.21 (−0.76, −0.08)	−0.25 (−0.62, −0.09)	−0.26 (−0.62, −0.12)	0.009
Entropy (SSF=4 mm)	2.37 (0.92–2.95)	2.47 (1.19–4.09)	2.50 (0.88, 3.26)	0.02
Minimum signal int ensity (SSF=6 mm)	−0.19 (−0.62, −0.07)	−0.23 (−0.59, −0.09)	−0.25 (−0.54, −0.12)	0.007
Entropy (SSF=6 mm)	1.77 (0.51, 2.59)	2.00 (0.56, 4.22)	2.09 (0.84, 3.08)	<0.001

HER2+=human epidermal growth factor receptor 2+, TNBC=triple negative breast cancer, SSF=spatial scaling factor